{"id":24572,"date":"2014-02-01T09:19:51","date_gmt":"2014-02-01T09:19:51","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=24572"},"modified":"2014-02-03T09:17:43","modified_gmt":"2014-02-03T09:17:43","slug":"boehringer-ingelheim-stops-development-of-deleobuvir-for-hcv","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/24572","title":{"rendered":"Boehringer Ingelheim stops development of deleobuvir for HCV"},"content":{"rendered":"<p><strong>On 23 January 2014, the community website HIVandhepatitis.com reported that Boehringer\u00a0Ingelheim\u00a0will stop development its non-nucleoside hepatitis C virus polymerase inhibitor\u00a0deleobuvir\u00a0(formerly BI 207127).<\/strong> [1]<\/p>\n<p>The decision was made based on blinded results from the Phase 3 HCVerso 1 and 2 trials, which evaluated a regimen consisting of deleobuvir, the HCV protease inhibitor faldaprevir (formerly BI 201335), and ribavirin.<\/p>\n<p>The company statement reported &#8220;a higher rate of premature discontinuations suggesting a lower efficacy rate compared to other interferon-free therapies in development. [&#8230;] Boehringer Ingelheim has therefore concluded that the expected therapeutic value of the deleobuvir-containing regimen would not justify further development.&#8221;<\/p>\n<p>The company will move forward with the submission process for\u00a0faldaprevir, which has shown promising results in combination with\u00a0pegylated\u00a0interferon and\u00a0ribavirin\u00a0in the\u00a0STARTVerso trials.<\/p>\n<p>Sources:<\/p>\n<p>HIV and Hepatitis.com. Boehringer Ingelheim halts testing of deleobuvir Hepatitis C regimens. (23 January 2014).<\/p>\n<p><a href=\"http:\/\/www.hivandhepatitis.com\/hcv-treatment\/experimental-hcv-drugs\/4491\">http:\/\/www.hivandhepatitis.com\/hcv-treatment\/experimental-hcv-drugs\/4491<\/a><\/p>\n<p>Boehringer Ingelheim announcement. January 17, 2013.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 23 January 2014, the community website HIVandhepatitis.com reported that Boehringer\u00a0Ingelheim\u00a0will stop development its non-nucleoside hepatitis C virus polymerase inhibitor\u00a0deleobuvir\u00a0(formerly BI 207127). [1] The decision was made based on blinded results from the Phase 3 HCVerso 1 and 2 trials, &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-24572","post","type-post","status-publish","format-standard","hentry","category-hepatitis-coinfection"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/24572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=24572"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/24572\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=24572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=24572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=24572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}